Cao Pharmaceuticals - Crunchbase Company Profile & Funding

Overview

Cao Pharmaceuticals

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Cao Pharmaceuticals

CB Rank

1036992

Cao Pharmaceuticals is an early clinical-stage oncology drug development company.

Founded

obfuscation

Private

Webster, Texas, United States

11-50

www.caopharmaceuticals.com/

Biotechnology

Medical Device

Oncology

Pharmaceutical

Key People

Zhisong Cao: Founder

Details

Legal Name

Cao Pharmaceuticals

Operating Status

Active

Company Type

For Profit

Founders

Zhisong Cao

About the Company

Cao Pharmaceuticals is an early clinical-stage oncology drug development company that is committed to developing effective drugs from a natural plant extract with very low or readily manageable toxicity for the treatment of all solid tumors and lymphoma. It was founded in 2014 and is headquartered in Webster, Texas.

Phone Number

832-283-7705

Contact Email

info@caopharmaceuticals.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

CZ48

CZ48 is a camptothecin derivative in Phase I clinical trials, designed to improve blood levels and efficacy compared to 9-NitroCamptothecin, with limited toxicity.

Pipeline Drugs

Cao Pharmaceuticals is developing next-generation camptothecin derivatives with increased activity and reduced toxicity, alongside an improved design of an existing CPT-based drug.